Results 121 to 130 of about 303,204 (352)

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies

ADMET and DMPK
Background and purpose: The delivery of therapeutics to the central nervous system (CNS) remains a major challenge due to the restrictive nature of the blood-brain barrier (BBB), a key evolutionary feature that preserves brain homeostasis.
Ronny Vargas, Noelia Martinez-Martinez, Catalina Lizano-Barrantes, Jorge Andrés Pacheco-Molina, Encarna García-Montoya, María Pilar Pérez-Lozano, Josep María Suñe-Negre, Carlos Suñe, Marc Suñe-Pou   +8 more
doaj   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Accomplishments and challenges in stem cell imaging in vivo. [PDF]

, 2019
Stem cell therapies have demonstrated promising preclinical results, but very few applications have reached the clinic owing to safety and efficacy concerns.
Bose, Rajendran JC, Mattrey, Robert F
core  

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Natural products as metabolic modulators to enhance cancer immunotherapy: reprogramming the tumor microenvironment

Frontiers in Immunology
Cancer remains a major global health challenge, and although immunotherapy has achieved remarkable breakthroughs, its efficacy is often limited by tumor-induced immunosuppression within the tumor microenvironment (TME).
Xiaoyu Fan, Shushu Guo, Shushu Guo, Wanfang Li, Wanfang Li, Yingyin Wang, Jie Bao, Jie Bao, Jiuming He, Jiuming He, Hongtao Jin, Hongtao Jin, Hongtao Jin   +12 more
doaj   +1 more source

Supplementary Table S7 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

, 2023
Wei Zhou, Peng Fang, Dongan Yu, Hongyuan Ren, Meng You, Long Yin, Fei Mei, Huikai Zhu, Zhenzhen Wang, Hui Xu, Yuxia Cao, Xiaowei Sun, Xiaohong Xu, Jianjun Bi, Jin Wang, Lanping Ma, Xin Wang, Lin Chen, Yongliang Zhang, Xiaowei Cen, Xi Zhu, Liguang Lou, Datao Liu, Xiaoding Tan, Jinliang Yang, Tao Meng, Jingkang Shen   +26 more
openalex   +1 more source

Supplementary Figure S6 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation [PDF]

, 2023
Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop‐Guevara, Cristina Molina, María Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero‐Iriarte, Marta Escorihuela, Enrique J. Arenas, Cristina Bernadó Morales, Noemí Haro, Francis J. Giles, Óscar J. Pozo, Josep M. Miquel, Paolo Nucíforo, Ana Vivancos, Marta Melé, Violeta Serra, Joaquı́n Arribas, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V. Tian   +30 more
openalex   +1 more source

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

FEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop   +3 more
wiley   +1 more source

Alternative Models for Anticancer Drug Discovery From Natural Products Using Binary Tumor‐Microenvironment‐on‐a‐Chip

Advanced Science
The efficacy evaluation of anticancer drugs derived from natural products has traditionally relied on animal models, highlighting the need for more efficient preclinical assessment platforms.
Youngwon Kim, Si Hyeon Chae, Dahae Lee, Bum Soo Lee, Jiseok Lim, Hyo‐Il Jung, Ki Hyun Kim, Bongseop Kwak   +7 more
doaj   +1 more source